ProfileGDS5678 / 1448265_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 60% 60% 60% 59% 60% 62% 70% 70% 60% 60% 60% 60% 60% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6896161
GSM967853U87-EV human glioblastoma xenograft - Control 23.5815460
GSM967854U87-EV human glioblastoma xenograft - Control 33.5954560
GSM967855U87-EV human glioblastoma xenograft - Control 43.546260
GSM967856U87-EV human glioblastoma xenograft - Control 53.5110259
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6559660
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8088762
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3204770
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.4207370
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.586760
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5832560
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5723560
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6142860
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5840560